NetworkNewsBreaks – CytoDyn Inc.’s (CYDY) PRO
Post# of 155662
(Total Views: 150)
Posted On: 11/16/2018 5:36:19 PM
NetworkNewsBreaks – CytoDyn Inc.’s (CYDY) PRO 140 HIV Monotherapy Trial Data Selected for Presentation at CROI 2019
Biotechnology company CytoDyn (OTCQB: CYDY) today announced that data from its ongoing investigative trial of PRO 140 (leronlimab) as a single subcutaneous therapy in HIV-1 infected patients was accepted for a poster presentation at next year’s Conference on Retroviruses and Opportunistic Infections (“CROI”). Vice President, Clinical Operations at Amarex Clinical Research Dr. Kush Dhody will present the abstract, “PRO 140 SC: Long-acting, Single-agent Maintenance Therapy for HIV-1 Infection,” at CROI 2019, to be held in Seattle March 4-7, 2019.
“We are highly encouraged by the recently reported data from our monotherapy trial for patients receiving once-weekly injections of PRO 140 700 mg,” CytoDyn President and CEO Nader Pourhassan, Ph.D., stated in the news release. “As previously announced, we plan to file a pivotal phase 3 protocol for PRO 140 as a monotherapy for HIV-infected patients before the end of this year. We are excited to share the most recent data from this important clinical trial at CROI, which each year attracts many of world’s leading clinicians in HIV research.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Biotechnology company CytoDyn (OTCQB: CYDY) today announced that data from its ongoing investigative trial of PRO 140 (leronlimab) as a single subcutaneous therapy in HIV-1 infected patients was accepted for a poster presentation at next year’s Conference on Retroviruses and Opportunistic Infections (“CROI”). Vice President, Clinical Operations at Amarex Clinical Research Dr. Kush Dhody will present the abstract, “PRO 140 SC: Long-acting, Single-agent Maintenance Therapy for HIV-1 Infection,” at CROI 2019, to be held in Seattle March 4-7, 2019.
“We are highly encouraged by the recently reported data from our monotherapy trial for patients receiving once-weekly injections of PRO 140 700 mg,” CytoDyn President and CEO Nader Pourhassan, Ph.D., stated in the news release. “As previously announced, we plan to file a pivotal phase 3 protocol for PRO 140 as a monotherapy for HIV-infected patients before the end of this year. We are excited to share the most recent data from this important clinical trial at CROI, which each year attracts many of world’s leading clinicians in HIV research.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)